Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    ARV-471

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Arvinas & Pfizer announce updated clinical data from Ph1b Trial of Vepdegestrant
    Arvinas & Pfizer announce updated clinical data from Ph1b Trial of Vepdegestrant

    18 May 2024

    // INDINPHARMAPOST

    https://www.indianpharmapost.com/diagnostic-center/arvinas-and-pfizer-announce-updated-clinical-data-from-phase-1b-trial-of-vepdegestrant-in-combination-with-palbociclib-15660

    INDINPHARMAPOST
    18 May 2024
    Share Share
    Arvinas, Pfizer Update Vepdegestrant + Palbociclib Phase 1b Data
    Arvinas, Pfizer Update Vepdegestrant + Palbociclib Phase 1b Data

    16 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/16/2883219/0/en/Arvinas-and-Pfizer-Announce-Updated-Clinical-Data-from-Phase-1b-Trial-of-Vepdegestrant-in-Combination-with-Palbociclib-IBRANCE.html

    GLOBENEWSWIRE
    16 May 2024
    Share Share
    Arvinas Vepdegestrant Posters At ESMO Breast Cancer Congress 2024
    Arvinas Vepdegestrant Posters At ESMO Breast Cancer Congress 2024

    09 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/09/2879260/0/en/Arvinas-Announces-Upcoming-Vepdegestrant-Poster-Presentations-at-the-2024-European-Society-for-Medical-Oncology-ESMO-Breast-Cancer-Annual-Congress.html

    GLOBENEWSWIRE
    09 May 2024
    Share Share
    Carrick Announces First Patient Dosed in Phase 1b/2 Trial of Samuraciclib
    Carrick Announces First Patient Dosed in Phase 1b/2 Trial of Samuraciclib

    14 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/14/2829038/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1b-2-Clinical-Trial-of-Samuraciclib-in-Combination-with-Vepdegestrant-in-Patients-with-Advanced-Breast-Cancer.html

    GLOBENEWSWIRE
    14 Feb 2024
    Share Share
    Arvinas and Pfizers Vepdegestrant (ARV-471) Receives FDA Fast Track Designation
    Arvinas and Pfizers Vepdegestrant (ARV-471) Receives FDA Fast Track Designation

    06 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/06/2824113/0/en/Arvinas-and-Pfizer-s-Vepdegestrant-ARV-471-Receives-FDA-Fast-Track-Designation-for-the-Treatment-of-Patients-with-ER-HER2-Metastatic-Breast-Cancer.html

    GLOBENEWSWIRE
    06 Feb 2024
    Share Share
    Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data
    Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data

    28 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/28/2787397/0/en/Arvinas-and-Pfizer-Announce-Updated-Vepdegestrant-ARV-471-Data-to-be-Presented-at-the-2023-San-Antonio-Breast-Cancer-Symposium.html

    GLOBENEWSWIRE
    28 Nov 2023
    Share Share